

CALL FOR PROPOSALS

Novel Therapeutics for Genetic Disease

CU Innovations is partnering with BridgeBio to develop new treatments for diseases with an underlying genetic basis. We are seeking researchers who have therapeutic technology they would like to advance toward clinical development. BridgeBio has initiated a call for proposals in the following areas of interest:

- **Genetic diseases** – e.g., Mendelian diseases, repeat expansion diseases, and cancers with germline or somatic driver mutations.
- **Proof of principle demonstrating a therapeutic can directly modulate the underlying genetic target** – e.g., directly inhibits a gain-of-function protein, addresses a loss-of-function, or directly compensates for the activity of a defective protein.

SELECTION CRITERIA

Genetics

- Is the disease characterized by a mutation?
- Is the therapy targeting the mutated protein or directly addressing the mutation's effect?
- Is there evidence the mutation is driving the pathology?

Molecular Mechanism

- How does the mutation change cell signaling?
- How does the mutation affect the structure-activity relationship of the target?
- Are there reliable animal models of the disease?

Patient Journey

- Is there a genotype-phenotype correlation?
- Is there natural history data?
- What do patients & families want addressed?
- What current standard of care is being improved?

Product

- Is there IP associated with the therapy?
- Is this a proven modality? (ex. antibody, AAV)
- How many patients will this product help?

Applications due by: Monday, May 12, 2021

Learn more & apply: bit.ly/bridgebio2021



About BridgeBio:

BridgeBio was founded in 2015 to identify and develop treatments that target well-characterized genetic diseases at their source. In service of its mission to bridge the gap between remarkable scientific innovation and patients with unmet needs, BridgeBio has a pipeline of over 20 development programs ranging from early discovery to late-stage development. BridgeBio invests in sponsored research, creates companies based on licensed technology, and makes lead investments into existing companies.